The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later

Control of canine leishmaniasis is an important objective for the benefit of dogs living in or visiting endemic areas and for public health because of the zoonotic nature of this disease. Resistance or susceptibility to developing canine leishmaniasis after exposure to Leishmania infantum is primari...

Descripción completa

Detalles Bibliográficos
Autores: Martin, Virginie, Vouldoukis, Ioannis, Moreno, Javier, McGahie, David, Gueguen, Sylvie, Cuisinier, Anne-Marie
Tipo de recurso: artículo
Fecha de publicación:2014
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/7035
Acceso en línea:http://hdl.handle.net/20.500.12105/7035
Access Level:acceso abierto
Palabra clave:Animals
Bone Marrow
Dog Diseases
Dogs
Female
Immunization Schedule
Leishmania infantum
Male
Parasite Load
Th1 Cells
Time Factors
Adaptive Immunity
Leishmaniasis Vaccines
id ES_e84ce2b58186520cebfcf2c7f8ebd50f
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/7035
network_acronym_str ES
network_name_str España
repository_id_str
spelling The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year laterMartin, VirginieVouldoukis, IoannisMoreno, JavierMcGahie, DavidGueguen, SylvieCuisinier, Anne-MarieAnimalsBone MarrowDog DiseasesDogsFemaleImmunization ScheduleLeishmania infantumMaleParasite LoadTh1 CellsTime FactorsAdaptive ImmunityLeishmaniasis VaccinesControl of canine leishmaniasis is an important objective for the benefit of dogs living in or visiting endemic areas and for public health because of the zoonotic nature of this disease. Resistance or susceptibility to developing canine leishmaniasis after exposure to Leishmania infantum is primarily determined by the ability of the immune system to develop an appropriate Th1-dominated specific response to the parasite. For this reason there is a need for effective canine vaccines that can decrease the number of dogs developing progressive infections. In this study, we followed the impact of the LiESP/QA-21 canine vaccine (composed of excreted-secreted proteins of L. infantum and the QA-21 saponin adjuvant), recently launched commercially in Europe, on selected humoral and cellular immune parameters following an infectious intravenous challenge with L. infantum promastigotes administered one year after the primary vaccine course. We also followed parasitological parameters to determine the parasitological status of the challenged dogs. In contrast to controls, vaccinated dogs retained significantly stronger cell-mediated immune responses against the parasite despite a virulent challenge and had significantly lower mean parasite burdens at the end of the study, associated with a lower probability of developing active infections. These results confirm that the immune responses generated by vaccination with LiESP/QA-21 are still effective against an intravenous challenge one year after the primary vaccine course.BioMed Central (BMC)Virbac (France)20192019-01-3020142014-06-2520142014-06-25journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/7035reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/70352026-06-12T12:43:37Z
dc.title.none.fl_str_mv The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later
title The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later
spellingShingle The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later
Martin, Virginie
Animals
Bone Marrow
Dog Diseases
Dogs
Female
Immunization Schedule
Leishmania infantum
Male
Parasite Load
Th1 Cells
Time Factors
Adaptive Immunity
Leishmaniasis Vaccines
title_short The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later
title_full The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later
title_fullStr The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later
title_full_unstemmed The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later
title_sort The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later
dc.creator.none.fl_str_mv Martin, Virginie
Vouldoukis, Ioannis
Moreno, Javier
McGahie, David
Gueguen, Sylvie
Cuisinier, Anne-Marie
author Martin, Virginie
author_facet Martin, Virginie
Vouldoukis, Ioannis
Moreno, Javier
McGahie, David
Gueguen, Sylvie
Cuisinier, Anne-Marie
author_role author
author2 Vouldoukis, Ioannis
Moreno, Javier
McGahie, David
Gueguen, Sylvie
Cuisinier, Anne-Marie
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Virbac (France)
dc.subject.none.fl_str_mv Animals
Bone Marrow
Dog Diseases
Dogs
Female
Immunization Schedule
Leishmania infantum
Male
Parasite Load
Th1 Cells
Time Factors
Adaptive Immunity
Leishmaniasis Vaccines
topic Animals
Bone Marrow
Dog Diseases
Dogs
Female
Immunization Schedule
Leishmania infantum
Male
Parasite Load
Th1 Cells
Time Factors
Adaptive Immunity
Leishmaniasis Vaccines
description Control of canine leishmaniasis is an important objective for the benefit of dogs living in or visiting endemic areas and for public health because of the zoonotic nature of this disease. Resistance or susceptibility to developing canine leishmaniasis after exposure to Leishmania infantum is primarily determined by the ability of the immune system to develop an appropriate Th1-dominated specific response to the parasite. For this reason there is a need for effective canine vaccines that can decrease the number of dogs developing progressive infections. In this study, we followed the impact of the LiESP/QA-21 canine vaccine (composed of excreted-secreted proteins of L. infantum and the QA-21 saponin adjuvant), recently launched commercially in Europe, on selected humoral and cellular immune parameters following an infectious intravenous challenge with L. infantum promastigotes administered one year after the primary vaccine course. We also followed parasitological parameters to determine the parasitological status of the challenged dogs. In contrast to controls, vaccinated dogs retained significantly stronger cell-mediated immune responses against the parasite despite a virulent challenge and had significantly lower mean parasite burdens at the end of the study, associated with a lower probability of developing active infections. These results confirm that the immune responses generated by vaccination with LiESP/QA-21 are still effective against an intravenous challenge one year after the primary vaccine course.
publishDate 2014
dc.date.none.fl_str_mv 2014
2014-06-25
2014
2014-06-25
2019
2019-01-30
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/7035
url http://hdl.handle.net/20.500.12105/7035
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central (BMC)
publisher.none.fl_str_mv BioMed Central (BMC)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422930117525504
score 15,812455

Similares en LA Referencia